CytoSorbents (CTSO) Awarded $3.8M Contract to Develop Sepsis Treatment Program
Company looks to advance polymer technologies as it meets key milestones set by Department of Defense’s Defense Advanced Research Projects Agency (DARPA) program. CytoSorbents Corp., a company using blood purification technology to treat life-threatening illnesses, today announced that it has received from DARPA a technology development contract worth up to $3.8 million as part of its Dialysis-Like Therapeutics (DLT) program to treat sepsis, an often fatal condition caused by microorganisms or toxins in the tissue or bloodstream. DARPA, an agency of the U.S. Department of Defense, is funding CytoSorbents’ development of a portable, artificially intelligent blood purification system capable of…